Cargando…
SUN-609 Livoletide (AZP-531), an Unacylated Ghrelin Analogue, Improves Hyperphagia and Food-Related Behaviors Both in Obese and Non-Obese People with Prader-Willi Syndrome
Prader-Willi syndrome (PWS) is a rare, complex neuro-developmental genetic disorder characterized by hyperphagia and abnormal food-related behaviors that contribute to severe morbidity and early mortality and to significant burden on patients and caregivers. While a majority of people with PWS is ob...
Autores principales: | Harisseh, Rania, Delale, Thomas, Yeh, Michael, Allas, Soraya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207881/ http://dx.doi.org/10.1210/jendso/bvaa046.1004 |
Ejemplares similares
-
MON-102 Nonclinical Development of AZP-531 (Livoletide): A Peptide Analog of Unacylated Ghrelin for the Treatment of Hyperphagia in Prader-Willi Syndrome
por: Milano, Stephane, et al.
Publicado: (2019) -
SUN-608 Juvenile Toxicity Study of Livoletide: A Peptide Analogue of Unacylated Ghrelin for the Treatment of Hyperphagia in Prader-Willi Syndrome
por: Xu, Howard, et al.
Publicado: (2020) -
SAT-100 Trial-in-Progress: ZEPHYR, a Pivotal Phase 2b/3 Randomized, Placebo-Controlled Study of Livoletide, a Novel Unacylated Ghrelin Analog, for the Treatment of Hyperphagia and Food-Related Behaviors in Patients with Prader-Willi Syndrome
por: Allas, Soraya, et al.
Publicado: (2019) -
AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial
por: Allas, Soraya, et al.
Publicado: (2018) -
Elevated ratio of acylated to unacylated ghrelin in children and young adults with Prader–Willi syndrome
por: Kuppens, R. J., et al.
Publicado: (2015)